Trials / Completed
CompletedNCT03569098
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum toxin type A | Investigators will inject the reconstituted solution into foot muscles. |
| DRUG | Placebo | Investigators will inject the reconstituted solution into foot muscles. |
Timeline
- Start date
- 2018-06-19
- Primary completion
- 2019-12-17
- Completion
- 2020-05-22
- First posted
- 2018-06-26
- Last updated
- 2021-07-02
- Results posted
- 2021-07-02
Locations
29 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03569098. Inclusion in this directory is not an endorsement.